As the field of mRNA-based medicines advances, both developers and regulatory agencies are prioritizing safety. The presence of double-stranded RNA (dsRNA) impurities, a byproduct of mRNA synthesis by in vitro transcription (IVT), can compromise the safety as well as the potency of mRNA vaccines and therapeutics. Don't miss this Fierce Biotech Webinar where we will introduce our innovative solutions that include Codex® HiCap T7 RNA Polymerase. The production of mRNA using HiCap minimizes dsRNA formation during IVT, which may eliminate the need for a secondary chromatography step in downstream purification. This paves the way for the development of safer and more potent mRNA-based medicines with simpler and more economical manufacturing workflows. Secure your spot today! https://lnkd.in/gsJcdZ2v
Aldevron
Biotechnology Research
Fargo, North Dakota 15,593 followers
The basis for breakthroughs
About us
Aldevron is proud to be part of Danaher. Danaher’s science and technology leadership puts Aldevron’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.
- Website
-
http://www.aldevron.com
External link for Aldevron
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Fargo, North Dakota
- Type
- Privately Held
- Founded
- 1998
- Specialties
- Plasmid DNA, Messenger RNA (mRNA), Recombinant Proteins, CRISPR/Cas9, cGMP, GMP-Source, Gene Therapy, Cell Therapy, Vaccine Development, and Gene Editing
Locations
-
Primary
4055 41st Ave S
Fargo, North Dakota 58104, US
-
5602 Research Park Blvd
Suite 112
Madison, Wisconsin 53719, US
-
3100 University Dr S
Fargo, North Dakota 58103, US
Employees at Aldevron
Updates
-
ICYMI With Biological Safety Levels (BSL), many gene therapy developers and manufacturers aim for BSL I in the manufacturing process. But as Aldevron’s Cody Grasswick points out, there are reasons to consider BSL II when some regulations and controls come into the mix. https://lnkd.in/g5XGFrmt
-
One of the issues in #RNA therapeutic development is the cost of the process, along with lengthy timelines. However, would the application of Moore’s Law for computing provide a roadmap to overcoming those obstacles? As Kyle Studey discusses in his post, Rise of the Machine, artificial intelligence (#AI) could be the next big step for drug developers. https://lnkd.in/gATPtHAs
-
-
With Biological Safety Levels (BSL), many gene therapy developers and manufacturers aim for BSL I in the manufacturing process. But as Aldevron’s Cody Grasswick points out, there are reasons to consider BSL II when some regulations and controls come into the mix. https://lnkd.in/gNeZZ-Pk
Should You Level Up Your BSL?
aldevron.com
-
Overcoming manufacturing challenges will be essential for large-scale use of mRNA therapies. A recent paper demonstrates how Codex® HiCap RNA Polymerase enables efficient co-transcriptional capping with reduced dsRNA byproducts. This enzyme is now available exclusively through Aldevron contact us to see how it can enhance IVT in your program. https://lnkd.in/gdBs7nc7
An engineered T7 RNA polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis
pubs.rsc.org
-
ICYMI When dealing with gene editing, delivery technologies are critical to success. As Max Sellman shares from the 2024 ASGCT annual meeting, lipid nanoparticles (LNP) are becoming more widely used as a non-viral delivery technology for #mRNA, with some new breakthroughs emphasizing their potential. https://lnkd.in/grE59wdG
-
-
“Our interns don’t just participate in the science, they learn how a high performing workplace culture operates from the inside and how to be part of a team,” said Tom Foti, Vice President and General Manager of Aldevron's Protein Business Unit. We enjoyed sharing a bit about our internship program here at Aldevron as a part of a feature story about our highly accomplished former intern, Nithesh Chandrasekharan, in this University of Wisconsin-Madison article: https://lnkd.in/g8SmAJt9. Nithesh, who was part of Aldevron’s 2023 cohort of graduate student interns, is pursuing a Ph.D. through the Integrated Program in Biochemistry (IPiB) at the University of Wisconsin-Madison. During the internship, Nithesh and the other interns actively participated in hands-on #biotech work at our Madison campus. “One of the biggest reasons I wanted to do an industry internship was that I wanted to see how bench science connects to the business and managerial side of biotech,” said Nithesh. We look forward to witnessing Nithesh and our other interns build strong careers in the industry! #AdvancingEveryDay
Graduate School Program Opens New Opportunities for International Students
-
We’re excited to see that the FDA has expanded the approval of Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), for nearly all patients. Congrats to Sarepta Therapeutics – this approval marks a significant milestone for patients with #DMD, a genetic disorder characterized by progressive muscle loss. We are proud to work with you! At Aldevron, we envision a world where every cure is possible, and yesterday was a great day! We look forward to witnessing and supporting continued advancements in treatments and cures for patients living with rare and more common diseases.
BREAKING: Today, we announced the U.S. FDA has expanded the product label for our gene therapy and more people may be able to receive treatment. Intended for U.S. audiences
-
-
“Smaller, safer plasmid DNA backbones are expanding the toolkit for CAR-T developers, helping them reach their goal of bringing life-saving cell therapies to a broader population of cancer patients.” CAR-T therapy holds tremendous promise, but its development also involves many complexities. As we strive to usher in more CAR-T innovations that will bring new cures and treatment for patients, plasmid DNA will play a critical role. Venkata Shravan K Indurthi, Chief Scientific Officer here at Aldevron, recently wrote about the importance of #plasmidDNA in CAR-T therapy development in @BioCompare here: https://lnkd.in/gwdpj_XP #CART #plasmid
How Improved DNA Plasmids Are Advancing CAR-T Development
biocompare.com